TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Safety and Dose Finding Trial of C-Tb, When Given to Adult Patients Recently Diagnosed With Active Tuberculosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~The patient:~1. Has signed an informed consent~2. Is willing and likely to comply with the trial procedures~3. Has been diagnosed with active TB and has been in treatment ≤ 60 days at the time of inclusion~   * has 1 documented positive sputum smear microscopy result~  * has positive culture~  * has a positive PCR result for tuberculosis~  * has a compatible clinical picture of TB with the intention to treat~4. Has a positive T-spot assay or a QuantiFERON®-TB Gold In Tube test~5. Is prepared to grant authorized persons access to their medical records~Exclusion Criteria:~The patient:~1. Has been in treatment with a product which is likely to modify the immune response within 3 months prior to the day of inclusion (e.g., immunoglobulin, systemic corticosteroids, methotrexate, azathioprine, cyclosporine or blood products)~2. Has been vaccinated with a live vaccine within 6 weeks prior to the day of inclusion (e.g. BCG, MMR, yellow fever, oral typhoid vaccines)~3. Has a known congenital or acquired immune deficiency~4. Has a disease affecting the lymphoid organs (e.g., Hodgkin's disease, lymphoma, leukaemia, sarcoidosis)~5. Is infected with HIV~6. Has severe scarring, burn, rash, eczema, psoriasis, or any other skin disease at or near the injection sites~7. Has a condition where blood drawings pose more than minimal risk for the patient, such as haemophilia, other coagulation disorders, or significantly impaired venous access~8. Is actively participating in another clinical trial~9. Is pregnant according to urine pregnancy test at inclusion~10. Has a condition which in the opinion of the investigator is not suitable for participation in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 0.01µg C-Tb (Type: EXPERIMENTAL): 12-24 patients depending on a safety evaluation will receive a low dose of 0.01 µg/0.1 mL C-Tb without phenol in the RIGHT or LEFT arm and 0.01 µg/0.1 mL C-Tb with phenol in the opposite arm, in a double blind manner.
- 0.1µg C.Tb (Type: EXPERIMENTAL): 12-24 patients depending on a safety evaluation will receive a high dose of 0.1 µg/0.1 mL C-Tb without phenol in the RIGHT or LEFT arm and 0.01 µg/0.1 mL C-Tb with phenol in the opposite arm, in a double blind manner.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study on the Effects of a Single Dose of Prednisone on Biomarkers of Allergen Responses in Asthmatics (MK-0000-175)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Has a clinical history of mild to moderate asthma for at least 6 months, but otherwise is in good health~* Participant with allergic rhinitis and asthma has a history of nonseasonal airway symptoms in response to aeroallergens OR has seasonal symptoms but can be evaluated out-of-season~* Is clinically stable and free of respiratory infection or change in allergen exposure for at least 4 weeks prior to start of study~Exclusion Criteria:~* Has intolerance to the study drug, inhaled salbutamol, antihistamines, or any other potential asthma/anaphylaxis rescue medication~* Has intolerance to lidocaine/lignocaine, sedatives, atropine or glycopyrrolate, or any other medication associated with bronchoscopy~* Has taken oral parenteral corticosteroids within 8 weeks or inhaled corticosteroids/nasal corticosteroids within 5 weeks of screening and/or during the study~* Has recent (4 weeks) or ongoing upper or lower respiratory tract infection~* Has active allergic rhinitis at screening~* Has received a vaccination within 3 weeks of screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Prednisone, then Placebo (Type: EXPERIMENTAL): Prednisone in the first crossover treatment period and placebo in the second crossover treatment period
- Placebo, then Prednisone (Type: EXPERIMENTAL): Placebo in the first crossover treatment period and prednisone in the second crossover treatment period

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Investigation to Optimize Hemodynamic Management of Left Ventricular Assist Devices Using the CardioMEMS™

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Subject has CardioMEMS HF PA Sensor and a commercially-approved HeartMate LVAD (Group A) OR Subject has commercially-approved HeartMate LVAD, is experiencing NYHA class III symptoms, and has had a previous HF hospitalization and meets FDA indications for CardioMEMS. The CardioMEMS PA Sensor must be implanted within 72 hours of consent (Group B)~2. Signed an informed consent form and agreed to provide access to patient and device data (including CardioMEMS Merlin.net data)~3. No connectivity or transmission problems with CardioMEMS~4. On HeartMate LVAD support for at least 3 months~5. Age ≥ 18 years~Exclusion Criteria:~1. Current participation in an investigation that is likely to confound study results or affect study outcome~2. Current participation in the MOMENTUM3 IDE Clinical trial and has not completed the two year follow-up for that trial~3. Inability to perform 6MHW test due to conditions other than heart failure (e.g. severe arthritis, orthopedic issues, amputation etc.)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group A: Patients with CardioMEMS PA Sensor and HeartMate LVAD prior to study enrollment (Type: None): Patients with CardioMEMS PA Sensor and LVAD, previously implanted, will receive hemodynamic management using CardioMEMS HF System
- Group B: Patients with existing HeartMate LVAD implanted with CardioMEMS PA Sensor post enrollment (Type: None): Patients with a HeartMate LVAD prior to study enrollment who are implanted with a CardioMEMS PA Sensor within 72 hours of study enrollment, will receive hemodynamic management using CardioMEMS HF System

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Therapeutic Effects of Sapropterin Dihydrochloride on Neuropsychiatric Symptoms in Phenylketonuria (PKU) Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ≥ 8 years of age~* Confirmed diagnosis of PKU~* Willing to continue current diet (typical diet for the 3 months prior to study entry) unchanged while participating in the study~* Willing and able to provide written, signed informed consent or in the case of subjects under the age of 18, provide written assent (if required) and written informed consent by a legally authorized representative after the nature of the study has been explained, and prior to any research-related procedures~* Sexually active subjects must be willing to use an acceptable method of contraception while participating in the study and for at least 30 days following the last dose of sapropterin dihydrochloride~* Females of childbearing potential must have a negative pregnancy test at screening and be willing to have additional pregnancy tests during the study. Females considered not of childbearing potential include those who have been in menopause at least 2 years, or had tubal ligation at least 1 year prior to screening, or have had total hysterectomy.~* Willing and able to comply with all study procedure~Exclusion Criteria:~* Has known hypersensitivity to sapropterin dihydrochloride or its excipients~* Subject breastfeeding at screening or planning to become pregnant (subject or partner) at any time during the study~* Use of any investigational product or investigational medical device within 30 days prior to screening, or requirement for any investigational agent prior to the completion of all scheduled study assessments~* Received sapropterin dihydrochloride within 16 weeks of randomization~* Have initiated or adjusted medication for treatment of ADHD, depression, or anxiety ≤ 8 weeks prior to randomization~* Taking medication known to inhibit folate synthesis (eg, methotrexate)~* Any condition requiring treatment with levodopa or any PDE-5 inhibitor~* Concurrent disease or condition that would interfere with study participation, compliance or safety as determined by the Investigator~* Any condition that, in the view of the Investigator, places the subject at high risk of poor treatment compliance or of not completing the study

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Sapropterin dihydrochloride (Type: EXPERIMENTAL): None
- Tablet without active ingredient (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: ADS-5102 for the Treatment of Levodopa Induced Dyskinesia (EASE LID Study)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed a current IRB/REB/IEC-approved informed consent form~* Parkinson's disease, per UK Parkinson's Disease Society (UKPDS) Brain Bank Clinical Diagnostic Criteria~* On a stable regimen of antiparkinson's medications for at least 30 days prior to screening, including a levodopa preparation administered not less than three times daily, and willing to continue the same doses and regimens during study participation~* Following diary training, the subject is willing and able to understand and complete the 24-hour PD home diary (caregiver/study partner assistance allowed)~* Any other current and allowed prescription/non-prescription medications and/or nutritional supplements taken regularly must have been at a stable dose and regimen for at least 30 days prior to screening, and subject must be willing to continue the same doses and regimens during study participation (this criterion does not apply to medications that are being taken pre-study only on an as-needed basis)~Exclusion Criteria:~* History of neurosurgical intervention related to Parkinson's disease (e.g. deep brain stimulation)~* History of seizures within 2 years prior to screening~* History of stroke or transient ischemic attack (TIA) within 2 years prior to screening~* History of cancer within 5 years prior to screening, with the following exceptions: adequately treated non-melanomatous skin cancers, localized bladder cancer, non-metastatic prostate cancer or in situ cervical cancer~* Presence of cognitive impairment, as evidenced by a Mini-Mental Status Examination (MMSE) score of less than 24 during screening~* If female, is pregnant or lactating~* If a sexually active female, is not surgically sterile or at least 2 years post-menopausal, or does not agree to utilize an effective method of contraception from screening through at least 4 weeks after the completion of study treatment.~* Treatment with an investigational drug or device within 30 days prior to screening~* Treatment with an investigational biologic within 6 months prior to screening~* Current participation in another clinical trial

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- ADS-5102 (Type: EXPERIMENTAL): ADS-5102 (amantadine HCl extended release)
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 7 Day Continuous Parathyroid Hormone IV Infusion

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: SINGLE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy Caucasian, Hispanic or Asian subjects~* Males and Females~* Non-smoker~* Ages 24 - 35 years old~* Subjects will be recruited either from the employee pool of the University of Pittsburgh or the University of Pittsburgh Medical Center (UPMC), or the general population living in the vicinity.~* Participation in this study by an employee or a potential employee at the University of Pittsburgh or UPMC has no effect on their employment or potential employment.~* Participants in the study will be required to discontinue all vitamins and health food supplements two weeks prior to the study.~Exclusion Criteria:~* Cardiac, hypertensive, vascular, renal (serum creatinine of \>1.5), pulmonary, endocrine, musculoskeletal, hepatic, hematologic or malignant or rheumatologic disease~* Body Mass Index (BMI) \> 30,~* Anemia (hematocrit less than 36% in women, less than 40% in men),~* Pregnancy (all women will have a urine pregnancy test performed immediately before starting the study and must not be pregnant)~* Significant alcohol or drug abuse or~* Baseline hypotension (systolic blood pressure less than 90 mm/Hg).~* Subjects will be excluded for abnormal levels of any of the screening labs including: ionized and total serum calcium, phosphorus, creatinine, albumin, 25-hydroxyvitamin D, and PTH. Pregnancy~* Subjects taking any chronic medications except oral contraceptives and stable doses of thyroid hormone, or those who have received any investigational drug in past 90 days will be excluded from the study.~* Subjects may not participate in this study more than once.~* Any subject who has previously received PTH or PTHrP, a related peptide, may not participate in this study.~Minority Inclusion/Exclusion Statement: We will not include African-Americans because this group has been demonstrated by a number of investigators to display resistance to PTH, and may create wider statistical variation and a need for larger numbers of study subjects per group.

- Gender: ALL
- Minimum Age: 24 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- Group 1 (Type: EXPERIMENTAL): Parathyroid Hormone (PTH) (1-34) 2 picomols/kg/hr for one week.
- Group 2 (Type: EXPERIMENTAL): Parathyroid Hormone (PTH) (1-34)4 picomols/kg/hr for one week.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Seventh Generation Bonding Agents as Short-Term Desensitizers Among Patients With Hypersensitivity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy males or females of 18 to 45 years of age~* Hypersensitive teeth to air and tactile stimultaion~* Gingival recession of Miller Class I and II~* Score 1 of Silness and Loe Plaque index~* Participants who have no sysytemic illness~* Patients who agree to give consent were included in the study.~Exclusion Criteria:~* Carious teeth~* Fractured restoration or cracked teeth~* Teeth undergoing orthodontic or periodontal treatment at sensitive site~* Patients who had dental bleaching in last 03 months~* Patients taking pain killers~* Smokers~* Pregnant and nursing females were excluded from the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Group-I Single Bond Universal (Type: ACTIVE_COMPARATOR): it is a seventh generation bonding agent used as desensitizer, manufactured by 3M ESPE.~applied on the affected surface of the group-I participants.
- Group-II Xeno V+ (Type: ACTIVE_COMPARATOR): it is a seventh generation bonding agent used as desensitizer, manufactured by Dentsply.~applied on the affected surface of the group-II participants.
- Group-III Bifluorid 12 (Type: PLACEBO_COMPARATOR): it is a fluoride varnish used as desensitizer, manufactured by VOCO. applied on the affected surface of the group-III participants.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Genotropin Treatment In Very Young Children Born Small For Gestational Age

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Caucasian male or female subjects aged between 19-29 months at Screening Visit 1.~Born SGA (birth length and/or weight \<-2 SD for gestational age, using country-specific standards).~Height below -2.5 SD at screening (19-29 months of age). At least one measurement of length between 12 and 18 months of age. Normal karyotype in girls to exclude Turners syndrome.~Exclusion Criteria:~Severe Intra-Uterine Growth Retardation (IUGR) (birth length below - 4 SD for gestational age), if associated with dysmorphic features.~Severe prematurity (Gestational Age (GA) \<32 weeks of gestation). Ongoing catch-up growth (defined as growth velocity SDS at inclusion \>0) based on at least 4 months measurement interval).~Severe familial short stature defined as: Father's height below 155 cm or mother's height below 145 cm.~Defined neurological defects and/or severe neurodevelopmental delay.

- Gender: ALL
- Minimum Age: 19 Months
- Maximum Age: 29 Months
- Healthy Volunteers: f

Study Arms:
- Active (Type: EXPERIMENTAL): The active treatment arm
- Control (Type: EXPERIMENTAL): Control

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluate ALLN-177 in Patients With Enteric Hyperoxaluria

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Provided informed consent~2. Age 18 or older~3. History of hyperoxaluria secondary to a known underlying enteric disorder associated with malabsorption (e.g., bariatric surgery, Crohn's disease, short bowel syndrome, or other malabsorption syndrome)~4. Urinary Oxalate ≥ 50mg/24h~Exclusion Criteria:~1. Acute renal failure or estimated glomerular filtration rate (eGFR) \< 30mL/min/1.73 m2~2. Unable or unwilling to discontinue Vitamin C supplementation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ALLN-177 (Type: EXPERIMENTAL): ALLN-177 3,750 units per capsule
- Placebo (Type: PLACEBO_COMPARATOR): Placebo capsule

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Heliox-Driven Racemic Epinephrine in Treatment of Bronchiolitis in Pediatric ED Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Any child 2-12 months old seen in the emergency department.~* A clinical bronchiolitis score \> 3 by modified Wood's Clinical Bronchiolitis Score (M-WCBS).~* Diagnostic criteria of bronchiolitis includes tachypnea, cough, prolonged expiratory phase, wheezing, rales, chest retractions, and hyperinflation of lungs on chest radiograph. After consenting a patient to the study, respiratory syncytial virus (RSV) infection will be tested by rapid enzyme-linked immunoabsorbent assay of nasal secretions.~Exclusion Criteria:~* No child will be excluded based on race or gender~* Patients under the age of 2 months or greater than 12 months~* Patients with cyanotic heart disease~* Patients with lobar pneumonia, defined by results of chest radiographs.~* The presence of interstitial disease or diffuse patchy marking consistent with atelectasis on chest radiographs will not exclude patients.~* Patients with croup.~* Patients with foreign body aspiration.~* Patients with history of cystic fibrosis, bronchopulmonary dysplasia or other chronic lung disease.~* Patients with liver or renal disease.~* Patients with sickle cell anemia.~* Patients requiring mechanical ventilation.~* Patients who develop supraventricular tachycardia secondary to racemic epinephrine administration.~* Patients with tracheomalacia or bronchomalacia.~* Patients who had received bronchodilators within 2 hours of initiation of the study.~* Patients who had received systemic corticosteroids within 72 hours of enrollment~* Patients who suffered from persistent airway hyperreactivity in the 3 months before the study.~* Patients who do not tolerate the nasal cannulae for 45 out of 60 minutes.

- Gender: ALL
- Minimum Age: 2 Months
- Maximum Age: 12 Months
- Healthy Volunteers: t

Study Arms:
- heliox (Type: OTHER): heliox-driven nebulizations for children with moderate to severe bronchiolitis
- oxygen (Type: OTHER): oxygen-driven nebulizations for children with moderate to severe bronchiolitis

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Oral Contraceptive Hormone-free Interval Pituitary/ Ovarian Activity

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Healthy, reproductive age women~* 18 to 35 years old,~* seeking contraception from the general gynecology clinics of the LAC and USC Medical Center w~* taking one of 6 possible monophasic COC formulations for at least 3 cycles prior to enrollment~* regular menstrual cycles prior to COCs~Exclusion Criteria:~* Irregular bleeding~* bilateral oophorectomy~* amenorrhea~* hormone-sensitive cancer~* concurrent medications known to interfere with steroid metabolism (i.e., barbiturates, phenytoin, carbamazepine, ethosuximide, primidone, rifampin, tetracycline)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: None

Study Arms:
- Healthy reproductive age women (Type: None): These volunteers were previously taking the oral contraceptives of interest for a minimum of 3 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete